WO2005003157A3 - Variantes de l'interferon a proprietes ameliorees - Google Patents

Variantes de l'interferon a proprietes ameliorees Download PDF

Info

Publication number
WO2005003157A3
WO2005003157A3 PCT/US2004/009824 US2004009824W WO2005003157A3 WO 2005003157 A3 WO2005003157 A3 WO 2005003157A3 US 2004009824 W US2004009824 W US 2004009824W WO 2005003157 A3 WO2005003157 A3 WO 2005003157A3
Authority
WO
WIPO (PCT)
Prior art keywords
improved properties
interferon variants
interferon
variants
properties
Prior art date
Application number
PCT/US2004/009824
Other languages
English (en)
Other versions
WO2005003157A2 (fr
Inventor
Anna Marie Aguinaldo
Amelia Joy Beyna
Ho Sung Cho
John Rudolph Desjarlais
Shannon Alicia Marshall
Umesh Muchhal
Michael Francis Aquin Villegas
Eugene Zhukovsky
Michael Stephen Quesenberry
Original Assignee
Xencor Inc
Anna Marie Aguinaldo
Amelia Joy Beyna
Ho Sung Cho
John Rudolph Desjarlais
Shannon Alicia Marshall
Umesh Muchhal
Michael Francis Aquin Villegas
Eugene Zhukovsky
Michael Stephen Quesenberry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/030802 external-priority patent/WO2004031352A2/fr
Application filed by Xencor Inc, Anna Marie Aguinaldo, Amelia Joy Beyna, Ho Sung Cho, John Rudolph Desjarlais, Shannon Alicia Marshall, Umesh Muchhal, Michael Francis Aquin Villegas, Eugene Zhukovsky, Michael Stephen Quesenberry filed Critical Xencor Inc
Priority to EP04785771A priority Critical patent/EP1636256A2/fr
Priority to CA002528964A priority patent/CA2528964A1/fr
Priority to AU2004253847A priority patent/AU2004253847A1/en
Publication of WO2005003157A2 publication Critical patent/WO2005003157A2/fr
Publication of WO2005003157A3 publication Critical patent/WO2005003157A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur des variantes de l'interféron à propriétés améliorées, et sur leurs méthodes d'utilisation.
PCT/US2004/009824 2003-06-10 2004-03-30 Variantes de l'interferon a proprietes ameliorees WO2005003157A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP04785771A EP1636256A2 (fr) 2003-06-10 2004-03-30 Variantes de l'interferon a proprietes ameliorees
CA002528964A CA2528964A1 (fr) 2003-06-10 2004-03-30 Variantes de l'interferon a proprietes ameliorees
AU2004253847A AU2004253847A1 (en) 2003-06-10 2004-03-30 Interferon variants with improved properties

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US47724603P 2003-06-10 2003-06-10
US60/477,246 2003-06-10
US48972503P 2003-07-24 2003-07-24
US60/489,725 2003-07-24
PCT/US2003/030802 WO2004031352A2 (fr) 2002-10-01 2003-09-30 Variants d'interferons presentant des proprietes ameliorees
US10/676,705 US20040137581A1 (en) 2002-10-01 2003-09-30 Interferon variants with improved properties
US10/676,705 2003-09-30
USPCT/US03/30802 2003-09-30

Publications (2)

Publication Number Publication Date
WO2005003157A2 WO2005003157A2 (fr) 2005-01-13
WO2005003157A3 true WO2005003157A3 (fr) 2005-02-24

Family

ID=34198925

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/009824 WO2005003157A2 (fr) 2003-06-10 2004-03-30 Variantes de l'interferon a proprietes ameliorees

Country Status (2)

Country Link
EP (1) EP1636256A2 (fr)
WO (1) WO2005003157A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7998469B2 (en) 2002-09-09 2011-08-16 Hanall Biopharma Co., Ltd. Protease resistant interferon beta mutants

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006111745A2 (fr) * 2005-04-20 2006-10-26 Viragen Incorporated Composition et methode de traitement de l'infection virale
US20080038224A1 (en) * 2006-03-28 2008-02-14 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
FR2907454B1 (fr) * 2006-10-18 2009-01-23 Biomethodes Sa Variants ameliores de l'interferon beta humain
CA2707840A1 (fr) 2007-08-20 2009-02-26 Allozyne, Inc. Molecules substituees par des acides amines
CN114835797A (zh) * 2015-11-16 2022-08-02 Ubi蛋白公司 用于延长蛋白质半衰期的方法
RU2650755C1 (ru) * 2017-05-24 2018-04-17 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Способ очистки лекарственного средства пролонгированного действия на основе рекомбинантного аналога интерферона альфа-17 для лечения вирусного гепатита С
CN112043685A (zh) * 2020-09-18 2020-12-08 深圳科兴药业有限公司 重组人干扰素α1b突变体吸入溶液及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048018A1 (fr) * 1997-04-23 1998-10-29 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. INTERFERON-β HUMAIN RECOMBINE A SOLUBILITE AMELIOREE
WO2002074783A2 (fr) * 2001-03-15 2002-09-26 Merck Patent Gmbh Interferon beta modifie a immunogenicite reduite

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048018A1 (fr) * 1997-04-23 1998-10-29 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. INTERFERON-β HUMAIN RECOMBINE A SOLUBILITE AMELIOREE
WO2002074783A2 (fr) * 2001-03-15 2002-09-26 Merck Patent Gmbh Interferon beta modifie a immunogenicite reduite

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARSHALL SHANNON A ET AL: "Rational design and engineering of therapeutic proteins.", DRUG DISCOVERY TODAY, vol. 8, no. 5, 1 March 2003 (2003-03-01), pages 212 - 221, XP002295833, ISSN: 1359-6446 *
RUNKEL LAURA ET AL: "Differences in activity between alpha and beta type I interferons explored by mutational analysis", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 273, no. 14, 3 April 1998 (1998-04-03), pages 8003 - 8008, XP002160242, ISSN: 0021-9258 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7998469B2 (en) 2002-09-09 2011-08-16 Hanall Biopharma Co., Ltd. Protease resistant interferon beta mutants
US8052964B2 (en) 2002-09-09 2011-11-08 Hanall Biopharma Co., Ltd. Interferon-β mutants with increased anti-proliferative activity
US8057787B2 (en) 2002-09-09 2011-11-15 Hanall Biopharma Co., Ltd. Protease resistant modified interferon-beta polypeptides

Also Published As

Publication number Publication date
WO2005003157A2 (fr) 2005-01-13
EP1636256A2 (fr) 2006-03-22

Similar Documents

Publication Publication Date Title
WO2005097825A3 (fr) Variants de bmp-7 ayant des proprietes ameliorees
AP2280A (en) Compositions and methods for increasing telomeraseactivity.
EP1664746A4 (fr) Capteur d'antioxydants, procedes et compositions associes
EP1660638A4 (fr) Lipoparticules comprenant des proteines, et procedes de production et d'utilisation de ces lipoparticules
IL211132A0 (en) Anti-il-6 antibodies, compositions, methods and uses
HK1086284A1 (en) Kid3 and anti-kid3 antibodies kid3 kid3
PL1651042T3 (pl) Kompozycja chwastobójcza o zwiększonym działaniu chwastobójczym i sposób zwiększania działania chwastobójczego
GB0413882D0 (en) Turbocharger
IL173521A0 (en) Substituted 2 - carbonylamino - 6 piperidinaminopyidines and substituted 1 - carbonylamino - 3 - piperidinaminobenzenes as 5 - th1f agonists
WO2004031352A3 (fr) Variants d'interferons presentant des proprietes ameliorees
AP2005003420A0 (en) Acidic composition and its uses.
EP1711527A4 (fr) Anticorps specifiques de hla-dr, compositions et methodes associees
WO2005110009A8 (fr) Compositions et methodes relatives aux tsp-30a, b, c et d
WO2005003157A3 (fr) Variantes de l'interferon a proprietes ameliorees
IL172184A0 (en) Interferon gamma - like protein
IL177759A0 (en) Cospeptin, cosmedin and their uses
GB0308013D0 (en) Turbocharger
WO2005009361A3 (fr) Methode de traitement a l'argatroban pour des patients souffrant de thrombocytopenie induite par l'heparine
GB2399268B (en) Throttle
AU2003232176A8 (en) Protein c variants with altered properties
AU2003247216A1 (en) Novel sphinogmyelinase, the antibody against it, the antisense and the preparation method thereof
AU2003286989A1 (en) The personal autoflusher
AU2003901418A0 (en) Sirna
AU2003906800A0 (en) Composition and Methods
AU2003901731A0 (en) Clip

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2528964

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004253847

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004785771

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004253847

Country of ref document: AU

Date of ref document: 20040330

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004253847

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004785771

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004785771

Country of ref document: EP